Skip to main content

Table 6 Relationship between double positivity of anti-nuclesome and anti-C1q antibodies and other disease parameters among patients under study

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Variable

n (%) or meanĀ±SD

Double Positive

(n=22)

Double Negative

(n=19)

t/xĀ²

P value

Clinical features

Arthritis

19 (86.4)

18 (94.7)

0.812

0.368

Pleurisy

14 (63.6)

13 (68.4)

0.104

0.747

Fever

14 (63.6)

7 (36.8)

2.930

0.087

Malar rash

11 (50.0)

14 (73.7)

2.403

0.121

Oral ulcers

12 (54.5)

9 (47.4)

0.21

0.647

Alopecia

10 (45.5)

9 (47.4)

0.015

0.902

Photosensitivity

6 (27.3)

11 (57.9)

3.939

0.047

Neurologic manifestations

5 (22.7)

6 (31.6)

0.407

0.524

APS

5 (22.7)

6 (31.6)

0.407

0.524

Vasculitis

8 (36.4)

1 (5.3)

5.756

0.016

Pericarditis

5 (22.7)

2 (10.5)

1.072

0.301

Discoid rash

3 (13.6)

1 (5.3)

0.812

0.368

Myositis

0 (0.0)

0 (0.0)

--

--

Nephritis

15 (68.18)

8 (42.1)

3.051

0.217

ECLAM

Ā 

4.6Ā±2.1

3.1Ā±2.1

2.254

0.030

Laboratory features

ESR (mm/1st hour)

59.6Ā±32.3

37.0Ā±25.1

2.471

0.018

Serum creatinine (Ī¼mol/L )

0.7Ā±0.3

0.9Ā±0.4

1.443

0.157

Serum albumin (g/dl)

3.6Ā±0.5

4.2Ā±0.8

2.960

0.005

Low C3 < 90 (mg/dl)

14 (63.6)

5 (26.3)

5.711

0.017

Low C4 < 10 (mg/dl)

7 (31.8)

5 (15.8)

1.420

0.233

24 hours urinary proteins (gm/24hrs)

2.1Ā±2.0

1.6Ā±1.5

0.606

0.551

  1. APS: Antiphospholipid syndrome, ESR: Erythrocyte sedimentation rate, ECLAM: European Consensus Lupus Activity Measurement